Drugs / Bimagrumab
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06890611 | Mar → Sep 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 213 trials · 5 met primary · 2 missed | ||||||
| Phase 2 | NCT05933499 | Nov 2025 → Dec 2028 expected | obesity disorder | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06901349 | May → Jun 2025 | obesity disorder | Eli Lilly and Company | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06643728 | Oct 2024 → Jan 2026 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05616013 | Nov 2022 → May 2024 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT03005288 | Feb 2017 → Mar 2019 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT02468674 | Jul 2015 → Dec 2018 | muscular atrophy | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT02333331 | Dec 2014 → Jun 2018 | muscular atrophy | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT02152761 | Sep 2014 → May 2018 | muscular atrophy | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01868685 | Apr 2014 → Jan 2015 | — | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01669174 | Sep 2012 → Dec 2014 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01601600 | Jan 2012 → Dec 2013 | skeletal muscle disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01423110 | Aug 2011 → May 2012 | inclusion body myositis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01433263 | Aug 2011 → Apr 2014 | hypoproteinemia, hypercatabolic | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT02250443 | Mar 2014 → Aug 2016 | inclusion body myositis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT01925209 | Sep 2013 → Jan 2016 | inclusion body myositis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT02573467 | Nov 2015 → Aug 2016 | inclusion body myositis | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bimagrumab | “Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.” PMID 30095981 ↗ Feb 201912“Treatment of sporadic inclusion body myositis with bimagrumab.” PMID 25381300 ↗ Nov 2014 |
| Known as | BYM338 | “This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab...” NCT02468674 ↗6“Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis.” PMID 32690797 ↗ Jul 2020 “Drug: BYM338/bimagrumab” NCT01925209 ↗ |
| Known as | O81t794r34 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137353 ↗ |
| Action | Inhibit | “blocks the activin type II receptors” PMID 30095981 ↗ Feb 20191“Activin receptor type-2B antagonist” CHEMBL3137353 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal antibody” PMID 30095981 ↗ Feb 2019 |
| Route | Intravenous | “30 mg/kg intravenously” PMID 30095981 ↗ Feb 2019 |
| Target | ACVR2B | “Activin receptor type-2B antagonist” CHEMBL3137353 ↗ |